Several studies have shown that enhanced expression of Sp1 is correlated with angiogenic potential and poor prognosis in GC, whereas low expression of Sp1 has been reported to be involved in cancer progression and metastasis and may lead to poor prognosis in intestinal-type GC [22,23,24]. Here, SP1 is linked to gastric cancer.